Free Trial

DBV Technologies (DBVT) Competitors

$0.80
+0.01 (+0.93%)
(As of 07/12/2024 08:51 PM ET)

DBVT vs. SOPH, JSPR, STRO, ADAP, PSTX, BDTX, SLDB, MGTX, MOLN, and TNYA

Should you be buying DBV Technologies stock or one of its competitors? The main competitors of DBV Technologies include SOPHiA GENETICS (SOPH), Jasper Therapeutics (JSPR), Sutro Biopharma (STRO), Adaptimmune Therapeutics (ADAP), Poseida Therapeutics (PSTX), Black Diamond Therapeutics (BDTX), Solid Biosciences (SLDB), MeiraGTx (MGTX), Molecular Partners (MOLN), and Tenaya Therapeutics (TNYA). These companies are all part of the "biological products, except diagnostic" industry.

DBV Technologies vs.

DBV Technologies (NASDAQ:DBVT) and SOPHiA GENETICS (NASDAQ:SOPH) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, dividends, earnings, valuation, profitability, community ranking, risk and institutional ownership.

SOPHiA GENETICS has a net margin of -113.71% compared to DBV Technologies' net margin of -530.89%. SOPHiA GENETICS's return on equity of -47.56% beat DBV Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
DBV Technologies-530.89% -56.76% -43.18%
SOPHiA GENETICS -113.71%-47.56%-35.80%

DBV Technologies received 382 more outperform votes than SOPHiA GENETICS when rated by MarketBeat users. However, 73.91% of users gave SOPHiA GENETICS an outperform vote while only 56.52% of users gave DBV Technologies an outperform vote.

CompanyUnderperformOutperform
DBV TechnologiesOutperform Votes
399
56.52%
Underperform Votes
307
43.48%
SOPHiA GENETICSOutperform Votes
17
73.91%
Underperform Votes
6
26.09%

71.7% of DBV Technologies shares are owned by institutional investors. Comparatively, 31.6% of SOPHiA GENETICS shares are owned by institutional investors. 1.9% of DBV Technologies shares are owned by insiders. Comparatively, 4.9% of SOPHiA GENETICS shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

DBV Technologies currently has a consensus target price of $6.67, indicating a potential upside of 733.33%. SOPHiA GENETICS has a consensus target price of $7.33, indicating a potential upside of 57.37%. Given DBV Technologies' higher probable upside, research analysts clearly believe DBV Technologies is more favorable than SOPHiA GENETICS.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
DBV Technologies
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
SOPHiA GENETICS
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, DBV Technologies had 2 more articles in the media than SOPHiA GENETICS. MarketBeat recorded 5 mentions for DBV Technologies and 3 mentions for SOPHiA GENETICS. DBV Technologies' average media sentiment score of 0.87 beat SOPHiA GENETICS's score of 0.43 indicating that DBV Technologies is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
DBV Technologies
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
SOPHiA GENETICS
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

DBV Technologies has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500. Comparatively, SOPHiA GENETICS has a beta of 1.06, indicating that its share price is 6% more volatile than the S&P 500.

DBV Technologies has higher earnings, but lower revenue than SOPHiA GENETICS. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DBV Technologies$15.73M4.91-$72.73M-$0.84-0.95
SOPHiA GENETICS$62.37M4.88-$78.98M-$1.12-4.16

Summary

DBV Technologies and SOPHiA GENETICS tied by winning 9 of the 18 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DBVT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DBVT vs. The Competition

MetricDBV TechnologiesBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$77.19M$3.00B$5.40B$8.72B
Dividend YieldN/A2.11%2.78%4.04%
P/E Ratio-0.9526.77126.3218.29
Price / Sales4.91311.192,179.4084.35
Price / CashN/A169.7836.4533.15
Price / Book0.553.914.944.46
Net Income-$72.73M-$44.32M$111.49M$215.59M
7 Day Performance-4.63%8.76%6.20%5.35%
1 Month Performance-19.19%-1.15%5.71%4.39%
1 Year Performance-76.74%-5.18%6.55%1.77%

DBV Technologies Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SOPH
SOPHiA GENETICS
1.5334 of 5 stars
1.53 / 5 stars
$4.58
+0.4%
$7.33
+60.1%
+1.7%$299.44M$62.37M-4.09430Short Interest ↑
News Coverage
JSPR
Jasper Therapeutics
1.9614 of 5 stars
1.96 / 5 stars
$19.87
-6.8%
$69.56
+250.1%
+35.5%$299.24MN/A-3.5345High Trading Volume
STRO
Sutro Biopharma
4.0223 of 5 stars
4.02 / 5 stars
$3.60
+7.1%
$12.50
+247.2%
-12.1%$294.46M$154.07M-1.91300Positive News
ADAP
Adaptimmune Therapeutics
1.8552 of 5 stars
1.86 / 5 stars
$1.19
-0.8%
$2.79
+134.2%
+42.1%$293.72M$60.28M-1.61449Short Interest ↑
News Coverage
PSTX
Poseida Therapeutics
3.6439 of 5 stars
3.64 / 5 stars
$2.98
+0.3%
$14.67
+392.2%
+76.8%$288.94M$82.50M-2.50335Positive News
BDTX
Black Diamond Therapeutics
1.5158 of 5 stars
1.52 / 5 stars
$5.13
+2.4%
$13.00
+153.4%
+16.5%$288.56MN/A-3.0954Short Interest ↑
SLDB
Solid Biosciences
3.4394 of 5 stars
3.44 / 5 stars
$7.01
+5.3%
$15.33
+118.7%
+61.1%$269.04M$8.09M-1.7888
MGTX
MeiraGTx
4.1108 of 5 stars
4.11 / 5 stars
$4.14
+2.7%
$26.00
+528.0%
-30.3%$266.23M$11.38M-3.54402Positive News
Gap Up
MOLN
Molecular Partners
0.4884 of 5 stars
0.49 / 5 stars
$6.77
+3.4%
$4.50
-33.5%
-5.9%$248.32M$7.84M-3.35167Short Interest ↓
Positive News
TNYA
Tenaya Therapeutics
1.6465 of 5 stars
1.65 / 5 stars
$3.07
+2.3%
$15.00
+388.6%
-36.1%$241.06MN/A-1.87140Gap Up

Related Companies and Tools

This page (NASDAQ:DBVT) was last updated on 7/15/2024 by MarketBeat.com Staff

From Our Partners